(Q53393938)

13 May 2018

http://europepmc.org/abstract/MED/11745182

title

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. (English)

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

1 reference

Kantarjian HM

1

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Shan J

2

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Smith T

3

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Talpaz M

4

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Kozuch P

5

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Rios MB

6

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Cortes J

7

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

Giles FJ

8

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

O'Brien S

9

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

language of work or name

English

0 references

publication date

1 November 2001

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

published in

Cancer

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

volume

92

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

issue

10

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

page(s)

2501-2507

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

cites work

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Chronic myelogenous leukemia: biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Multiple-drug chemotherapy for acute leukemia.The TRAMPCOL regimen: Results in 86 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Terminal-phase chronic myelogenous leukemia: approaches to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Phase II study of carboplatin in blast crisis of chronic myeloid leukemia: Eastern Cooperative Oncology Group Study E1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Treatment results of 69 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820011115%2992%3A10%3C2501%3A%3AAID-CNCR1600%3E3.0.CO%3B2-N

10.1002/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

http://europepmc.org/abstract/MED/11745182

1 reference

13 May 2018